EXPRESS MAIL CERTIFICATE

Date 5/25/01 Label No. EL 706741438 US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

B.W. LEE
Name (Print)

B. W. Lee
Signature

PLEASE CHARGE ANY DEFICIENCY UP TO $300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Docket No.: 2292/0H795

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Robert Ian LECHLER; Anthony DORLING

Serial No.: 09/674,462

Filed: October 30, 2000

For: IMMUNOSUPPRESSION BY BLOCKING T CELL CO-STIMULATION SIGNAL 2 (B7/CD28 INTERACTION)

May 24, 2001

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is

not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The undersigned is also enclosing herewith a copy of a Search Report issued April 30, 1999 for the PCT counterpart of the present patent application (Application No. PCT/GB99/01350), in which the presently disclosed references were cited. The Search Report use the symbols "A" [document defining the general state of the art which is not considered to be of particular relevance] and "X" [document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone]. Since a translation of the Search Report is also enclosed, or the Search Report utilizes conventional codes to characterize each cited reference, it is believed that the applicants in the above-identified patent application have now met the "concise explanation" requirement of 37 C.F.R. 1.98.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be

construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Paul F. Fehlner

Paul F. Fehlner, Ph.D.
Registration No. 35,135
Attorney for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, NY 10022
(212) 527-7700

M:\2292\0H795\SG9200.WPD

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE (REV. 7-80)

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.:	2292/0H795	SERIAL NO:	09/674,462
APPLICANT:	Robert Ian LECHLER	FILING DATE:	October 30, 2000

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	1. WO 95/34320	12/21/95	WO				

OTHER REFERENCES
(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)

2. International Search Report from PCT/GB99/01350 (Published as WO 99/57266)

3. Baliga P, Chavin KD, Qin L. Woodward J, Lin J, Linsley PS, Bromberg JS. CTLA41g prolongs allograft survival while suppressing cell mediated immunity. Transplantation 1994: 58: 1082.

4. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei- R-Q, Gibson ML, Xhen Z-G, Myrdal S, Gordon D, Bailey T, Bolling SF, Thompson CB. T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Pro Natl Acad Sci USA 1992: 89: 11102.

5. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turha LA. Long term acceptance of major histocompatibility complex mismatched cardiac allograft induced by CTLA4-1g plus donor specific transfusion. J Exp Med 1993: 178: 1801.

6. Lenschow DJ, Zeng Y, Thistlewaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA. Long Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4-1g. Science 1992: 257: 789.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE (REV. 7-80)

LIST OF REFERENCES CITED BY APPLICANT
(Use Several Sheets if Necessary)

DOCKET NO.:	2292/0H795	SERIAL NO:	09/674,462
APPLICANT:	Robert Ian LECHLER	FILING DATE:	October 30, 2000

*EXAMINER
INITIALS

7. Dorling A, Lechler RI. T cell-mediated xenograft rejection: specific tolerance is probably required for long term xenograft survival. Xenotransplantation 1998: 5: 234.

8. Madsen JC, Superina RA, Wood KJ, Morris PJ. Immunological unresponsiveness induced by recipient cells transected with donor MHC genes. Nature 1988:332:161.

9. Saitovitch D. Morris PJ, Wood KJ. Recipient cells expressing single donor MHC locus products can substitute for donor-specific transfusion in the induction of transplantation tolerance when pretreatment is combined with anti-CD4 monoclonal antibody.

10. Wong W, Morris PJ, Wood KJ. Syngeneic bone marrow expressing a single donor class 1MHC molecule permits acceptance of a fully allogeneic cardiac allograft. Transplantation 1996:62:1462.

11. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988:9:23.

12. Sykes M. Chimerism and central tolerance. Curr Opin Immunol 1996: 8: 694.

13. Dono K, Maki T, Wood ML, Monaco AP. Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental rapamycin. Transplantation 1995:60:1268.

14. Carr RI, Zhou J, Ledingham D, Maloney C, McAlister V, Samson M, Bitter-Suermann H, Lee TD. Induction of transplantation tolerance by feeding or portal vein injection pretreatment of recipient with donor cells. Ann NY Acad Sci 1996:77B:368.

15. Margulies DH, Evans GA, Ozato K, Camerini OR, Tanaka K, Appella E, Seidman JG. Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer. J Immunol 1983:130:463.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE (REV. 7-80)

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.:	2292/0H795	SERIAL NO:	09/674,462
APPLICANT:	Robert Ian LECHLER	FILING DATE:	October 30, 2000

*EXAMINER
INITIALS

16. Krummel MF, Allison JP. CTLA-14 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996: 183: 2533.

17. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation [see comments]. J Exp Med 1995: 182: 459.

18. Valdivia LA, Monden M, Gotoh M, Tono T, Nakano Y, Mori T. Suppressor cells induced by donor-specific transfusion and deoxyspergualin in rat cardiac xenografts. Transplantation 1991:52:594.

19. Roelen DL, Dover EL, Niimi M, Young NT, Morris PJ, Wood KJ. Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness. Eur J Immunol 1996:26:1468.

20. van Twyver E, Mooijaart RJD, Ten Berge IJM, van der Horst AR, Wilmink JM, Kast WM, Melief CJM, De Waal LP. Pretransplantation blood transfusion revisited. N Engl J Med 1991:325:1210.

21. Lagaaij, Emma L., MD, et al; "Effect of One-HLA-DR-Antigen-Matched and Completely HLA-DR-Mismatched Blood Transfusions on Survival of Heart and Kidney Allografts", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 321, 14 September 1989, pages 701-705

*EXAMINER
INITIALS

EXAMINER: _____ DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE (REV. 7-80)

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.:	2292/0H795	SERIAL NO:	09/674,462
APPLICANT:	Robert Ian LECHLER	FILING DATE:	October 30, 2000

*EXAMINER
INITIALS

16. Krummel MF, Allison JP. CTLA-14 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996: 183: 2533.

17. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation [see comments]. J Exp Med 1995: 182: 459.

18. Valdivia LA, Monden M, Gotoh M, Tono T, Nakano Y, Mori T. Suppressor cells induced by donor-specific transfusion and deoxyspergualin in rat cardiac xenografts. Transplantation 1991:52:594.

19. Roelen DL, Dover EL, Niimi M, Young NT, Morris PJ, Wood KJ. Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness. Eur J Immunol 1996:26:1468.

20. van Twyver E, Mooijaart RJD, Ten Berge IJM, van der Horst AR, Wilmink JM, Kast WM, Melief CJM, De Waal LP. Pretransplantation blood transfusion revisited. N Engl J Med 1991:325:1210.

21. Lagaaij, Emma L., MD, et al; "Effect of One-HLA-DR-Antigen-Matched and Completely HLA-DR-Mismatched Blood Transfusions on Survival of Heart and Kidney Allografts", THE NEW ENGLAND JOURNAL OF MEDICINE, Vol. 321, 14 September 1989, pages 701-705

*EXAMINER
INITIALS

EXAMINER: _____ DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.